Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital.
about
Clinical Utility of Laboratory Detection of Clostridium difficile Strain BI/NAP1/027Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty?Defining the causes of diarrhea: novel approaches.Clostridium difficile infection in the inflammatory bowel disease patient.Clostridium difficile 027 infection in Central ItalyComparison of strain typing results for Clostridium difficile isolates from North America.Estimating risk of C. difficile transmission from PCR positive but cytotoxin negative cases.Clinical and laboratory characteristics of Clostridium difficile infection in patients with discordant diagnostic test resultsReducing Unnecessary and Duplicate Ordering for Ovum and Parasite Examinations and Clostridium difficile PCR in Immunocompromised Patients by Using an Alert at the Time of Request in the Order Management SystemComparison of BD GeneOhm Cdiff and Seegene Seeplex ACE PCR assays using toxigenic Clostridium difficile culture for direct detection of tcdB from stool specimens.Evaluation of Xpert C. difficile, BD MAX Cdiff, IMDx C. difficile for Abbott m2000, and Illumigene C. difficile Assays for Direct Detection of Toxigenic Clostridium difficile in Stool Specimens.A Diagnostic Algorithm for the Detection of Clostridium difficile-Associated DiarrheaPerformance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity.The Antimicrobial Stewardship Approach to Combating Clostridium Difficile.Transmission of Clostridium difficile During Hospitalization for Allogeneic Stem Cell Transplant.Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.Evaluation of a new automated homogeneous PCR assay, GenomEra C. difficile, for rapid detection of Toxigenic Clostridium difficile in fecal specimens.Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool.Epidemiology, diagnosis and treatment of Clostridium difficile infection.Using rapid diagnostic tests to optimize antimicrobial selection in antimicrobial stewardship programs.Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation.Real-time cellular analysis for quantitative detection of functional Clostridium difficile toxin in stool.Detection of gastrointestinal pathogens in oncology patients by highly multiplexed molecular panels.Comparison of Multilocus Sequence Typing and the Xpert C. difficile/Epi Assay for Identification of Clostridium difficile 027/NAP1/BI.Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review.Current knowledge on the laboratory diagnosis of Clostridium difficile infection.A Regional Outbreak of Clostridium difficile PCR-Ribotype 027 Infections in Southeastern France from a Single Long-Term Care Facility.Emergence of Clostridium difficile tcdC variant 078 in Marseille, France.Diagnosis and outcome of Clostridium difficile infection by toxin enzyme immunoassay and polymerase chain reaction in an island population.Diagnosis of Clostridium difficile: real-time PCR detection of toxin genes in faecal samples is more sensitive compared to toxigenic culture.Comparison of GenomEra C. difficile and Xpert C. difficile as confirmatory tests in a multistep algorithm for diagnosis of Clostridium difficile infection.Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection.Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the tcdC genotype and toxin production.Clostridium difficile Infection (CDI) in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.Detection of toxigenic Clostridium difficile: comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays.Accuracy of Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection: A meta analysis.Presumptive identification of Clostridium difficile strain 027/NAP1/BI on Cepheid Xpert: interpret with caution.Clostridium difficile 027 emerging outbreak in Marseille, France.Potential of real-time PCR threshold cycle (CT) to predict presence of free toxin and clinically relevant C. difficile infection (CDI) in patients with cancer.Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program.
P2860
Q26778127-C6F1ECCA-24B5-4C62-83E3-0D9A11A91526Q26827536-C2C3E771-6065-42D9-8461-EADF4141E03BQ30424695-5DFA2B5F-EB10-4329-8EE9-6818E5D36102Q34234668-C75F83AD-715B-4218-876E-A10C7811E281Q34520307-9DED278D-6D37-4745-9E23-1D7C0C089F5FQ34627447-29F2293E-C4D6-497B-B321-27023267E97EQ35093580-CCD9C88A-DBA8-45CF-BFAB-494C85DE70CDQ35867764-8F33AE0D-2A9B-4DC8-B95A-E119BD33C612Q35868657-0D9DC2D5-C1C7-4791-B2B6-DE744D73AC7EQ36363103-B6B8D0F5-5C10-4DB4-9424-C62852A4C707Q36465447-AA290287-CE52-4ECD-A8D2-7C83326613FBQ36618454-AC6DAC2B-EDD1-48D9-83B7-65140EC39701Q36667575-833A7982-CBF5-44A6-AF13-B894EE2CBF5BQ36683557-E4099B7C-4B4D-4199-AB0B-D8A4B9155EA7Q36977948-FAFA2076-C345-4D11-B617-B7F3322F72C9Q37035829-03C7675B-2751-4AE3-93EA-81732477CC81Q37125031-5354430A-8C8F-4D24-94D0-F5CBF4734804Q37713428-40AF6CA4-43BC-4436-B095-911874200DC8Q38068605-7DB21E06-F86F-4A7C-99D4-7F32B241244DQ38073195-41F0C113-A723-4251-9BA0-610D48AB4887Q38175865-D54DC31F-B237-4DC0-AC1A-64A9DF1E0914Q38197671-4B048BA7-5F44-48CA-928B-80AA0FFBAFB5Q38374878-1E6B056A-5575-4F39-8F35-7FAE58287A4BQ38637024-CFA3D0AF-4E9D-4622-8304-EEC84103FA5BQ38764998-A8222A74-A0A2-44A4-9A4B-975DEAE894FAQ39188881-0FAC14F0-EAF3-419E-AF1F-D0606EFD9CEBQ39532441-4B618C98-63F3-422D-8B08-E02B362DD783Q40176526-36F10DE0-19F3-43C8-B7DF-59EC97692D10Q40582745-51363320-9435-422A-9129-4C6F0E7F78FFQ41650253-6B6D8955-BA51-4741-B8CE-0AB7E74F5BEEQ41665158-8C5531D1-8DCB-4086-9823-C84645551D93Q41850630-21ACD35E-E809-4A1D-9801-1D22488400AAQ42115469-1164345C-6116-46C0-A332-5AAB146FAA8DQ42212406-057E2E7B-7DA4-4A3C-8028-189D4869C5A5Q42558740-CC517A6C-AEA3-49CC-A57E-C519834B01AAQ42708367-ED38FD82-4090-4B4B-BF08-8B2819F9069BQ42931684-6A5ED5B5-349B-42EF-A61E-A6739104755FQ46588071-82FDA5EE-873E-4DAA-8C1F-AE23362F0F66Q49923168-EFB03AD6-94FD-4093-9136-8545475514E3Q51317741-A8EEF5DB-7BCB-4208-A286-AE5EAB82517E
P2860
Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Evaluation of the Cepheid Xper ...... 1 strain at a cancer hospital.
@en
type
label
Evaluation of the Cepheid Xper ...... 1 strain at a cancer hospital.
@en
prefLabel
Evaluation of the Cepheid Xper ...... 1 strain at a cancer hospital.
@en
P2093
P2860
P356
P1476
Evaluation of the Cepheid Xper ...... 1 strain at a cancer hospital.
@en
P2093
David Huang
Jeffrey Stiles
Mini Kamboj
N Esther Babady
Perminder Khosa
Phyllis Ruggiero
Susan Shuptar
Timothy E Kiehn
P2860
P304
P356
10.1128/JCM.01648-10
P407
P577
2010-10-13T00:00:00Z